HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Reaction

Potassium Carbonate → 2-(4-(trifluoromethyl)benzyl)-7-(4-chlorophenyl)-8-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one

HRID 271401
Print

Reaction equation

HRID 271401 reaction equation
[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([C:8]2[N:13]=[CH:12][N:11]3[C:14](=[O:17])[NH:15][N:16]=[C:10]3[C:9]=2[C:18]2[CH:23]=[CH:22][CH:21]=[CH:20][CH:19]=2)=[CH:4][CH:3]=1.ClC1C=CC(C2N=CN=C(NNC(OC(Cl)(Cl)Cl)=O)C=2C2C=CC=CC=2)=CC=1.Br[CH2:53][C:54]1[CH:59]=[CH:58][C:57]([C:60]([F:63])([F:62])[F:61])=[CH:56][CH:55]=1.C([O-])([O-])=O.[K+].[K+]>CC(C)=O>[F:61][C:60]([F:62])([F:63])[C:57]1[CH:58]=[CH:59][C:54]([CH2:53][N:15]2[C:14](=[O:17])[N:11]3[CH:12]=[N:13][C:8]([C:5]4[CH:4]=[CH:3][C:2]([Cl:1])=[CH:7][CH:6]=4)=[C:9]([C:18]4[CH:23]=[CH:22][CH:21]=[CH:20][CH:19]=4)[C:10]3=[N:16]2)=[CH:55][CH:56]=1
ParticipantsConditionsProcedureWorkupSources & evidenceReaction notes

Participants

6

Reactant 4

HCID 11430Potassium CarbonateHCID 1230621-(Bromomethyl)-4-(trifluoromethyl)benzeneHCID 58772821Trichloromethyl 2-(6-(4-chlorophenyl)-5-phenylpyrimidin-4-yl)hydrazinecarboxylateHCID 587728227-(4-chlorophenyl)-8-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one

Product 1

HCID 15953665
2-(4-(trifluoromethyl)benzyl)-7-(4-chlorophenyl)-8-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one

Reagents, catalysts & solvents 1

HCID 180AcetoneSolvent

Conditions

Temperature
60 °C

Procedure

To a stirred solution of 7-(4-chlorophenyl)-8-phenyl-[1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one and/or trichloromethyl 2-(6-(4-chlorophenyl)-5-phenylpyrimidin-4-yl)hydrazinecarboxylate (16.0 mg, 0.05 mmol) in acetone (5 mL) at room temperature under argon was added 1-(bromomethyl)-4-(trifluoromethyl)benzene (23.9 mg, 0.10 mmol), followed by K2CO3 (13.8 mg, 0.10 mmol). The resulting mixture was heated at 60° C. for 24 h. Insoluble material was filtered and rinsed with CH2Cl2. The filtrate was concentrated under reduced pressure and purified by reverse phase preparative HPLC (without TFA). Further purification was performed by silica gel column chromatography eluting with EtOAc-hexanes. Pure product was lyophilized from 1,4-dioxane to obtain the title compound (5.0 mg) as an off-white lyophilate. HPLC/MS: retention time=4.18 min. [M+H]30 =481. 1H NMR (CDCl3): δ 8.70 (s, 1H), 7.65 (d, J=7.3 Hz, 2H), 7.55 (d, J=7.3 Hz, 2H), 7.23-7.46 (m, 7H), 7.20 (d, J=7.2 Hz, 2H), 5.18 (s, 2H).

Workup

  1. filtrationInsoluble material was filtered
  2. washrinsed with CH2Cl2
  3. concentrationThe filtrate was concentrated under reduced pressure
  4. custompurified by reverse phase preparative HPLC (without TFA)
  5. customFurther purification
  6. washeluting with EtOAc-hexanes

Sources & evidence

ORD record
ord-3e5b8a1393214b91adc9e0e99f62e98e
Source dataset
uspto-grants-2008_11
DOI
10.6084/m9.figshare.5104873.v1
Patent number
US07452892B2

Reaction notes

On this pageParticipantsConditionsProcedureWorkupSources & evidenceReaction notes